Trials / Completed
CompletedNCT03066752
Cognitive Dysfunction in MS: Using Altered Brain Oscillation to Link Molecular Mechanisms With Clinical Outcomes
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (actual)
- Sponsor
- The Hospital for Sick Children · Academic / Other
- Sex
- All
- Age
- 6 Years – 18 Years
- Healthy volunteers
- Accepted
Summary
Up to 65% of patients with multiple sclerosis (MS) experience cognitive dysfunction. Diminution of mental capacity has a pervasive and profound impact on their quality of life. Subtle changes in white matter predict cognitive changes in these patients but how this disrupts brain function remains unclear. Development of effective therapeutics to restore normal cognition hinges on elucidating these functional changes. The investigators seek to uncover the patho-physiological basis for cognitive decline in MS. The investigators hypothesize that cognitive decline originates from disrupted gamma oscillations and that gamma oscillations are disrupted by molecular changes triggered by demyelination.
Conditions
Timeline
- Start date
- 2017-03-27
- Primary completion
- 2017-11-24
- Completion
- 2017-11-24
- First posted
- 2017-02-28
- Last updated
- 2020-01-07
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT03066752. Inclusion in this directory is not an endorsement.